21 Nov 2012, BioSpectrum Bureau , BioSpectrum
Mumbai: Lupin's subsidiary Lupin Pharmaceuticals, US, launched its Fenofibrate tablets (48 mg and 145 mg strengths) in the US. Lupin had earlier received final approval for the same from the US FDA.
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR tablets and are indicated for primary hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia. Abbott's TRICOR tablets, which are available in 48 mg and 145 mg, recorded sales of $1.26 billion as per IMS Health, untill June 2012.
Commenting on the approval, Ms Vinita Gupta, CEO, Lupin Pharmaceuticals and group president, Lupin, said that, "We are very happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price."